NYSE:AIM
AIM ImmunoTech Inc. Stock News
$0.362
-0.0010 (-0.275%)
At Close: May 31, 2024
AIM ImmunoTech engages CRO Amarex Clinical Research to manage Phase 2 of Ampligen study
09:01am, Tuesday, 12'th Apr 2022
AIM ImmunoTech Inc (NYSE:AIM). has engaged Amarex Clinical Research LLC to manage the Phase 2 study of its flagship drug candidate Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
01:36pm, Monday, 11'th Apr 2022 PennyStocks
What you need to know about trading penny stocks on April 11th
The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informat
AIM ImmunoTech Inc (NYSE:AIM) presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship drug Ampligen (rintatolimod) as
AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver
11:05am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046)
AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer
11:05am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
09:36am, Monday, 11'th Apr 2022
What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informat
AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting
09:30am, Monday, 11'th Apr 2022
AIM ImmunoTech Inc (NYSE: AIM) has announced the presentation of positive data from a Phase 1 study of Ampligen in metastatic triple-negative breast cancer. The pre-determined primary efficacy endp
AIM ImmunoTech报告2021年第四季度和全年财务业绩并通报企业最新情况
02:31am, Saturday, 02'nd Apr 2022 GlobeNewswire Inc.
- 该年度继续执行临床开发项目并不断累积越来越多的在多个高价值的适应症中使用Ampligen®的积极数据
AIM ImmunoTech reports ‘strong' balance sheet to fund operations and clinical development programs through 2023
08:54am, Friday, 01'st Apr 2022
AIM ImmunoTech Inc (NYSE:AIM) said it has a “strong” balance sheet that will fund operations and clinical development programs through 2023. In a statement reporting its financial results for 20
AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress
11:35am, Monday, 28'th Mar 2022 GlobeNewswire Inc.
OCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape
AIM ImmunoTech says data from Ampligen study on pancreatic cancer accepted for presentation at upcoming IHPBA World Congress
09:18am, Monday, 28'th Mar 2022
AIM ImmunoTech Inc (NYSE:AIM) said data from a study evaluating the direct effects of its flagship drug candidate Ampligen (rintatolimod) on human pancreatic ductal adenocarcinoma (PDAC) cells has b
AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual Meeting
02:10pm, Thursday, 24'th Mar 2022 GlobeNewswire Inc.
OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape
AIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
12:05pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
Company to participate in live panel, “Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology,” on Monday, March 28th at 12:00 PM ET Company to participate in
AIM ImmunoTech获美国FDA的IND许可以推进Ampligen®治疗局部晚期胰腺癌的2期研究
10:08pm, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
迄今为止的数据表明Ampligen®(rintatolimod)可能成为晚期胰腺癌患者系统化疗后的一种潜在的有效维持疗法
AIMイムノテック（AIM ImmunoTech）が米国FDAからIND認可を受け、局所進行膵臓がんの治療におけるAmpligen®の第2相試験へ
10:08pm, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
これまでに確認されたデータは、アンプリジェン（アンプリゲン）（Ampligen®）（リンタトリモッド（rintatolimod））が進行性膵臓がん患者の全身化学�
